Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Titan Pharmaceuticals, Inc.    TTNP

TITAN PHARMACEUTICALS, INC.

(TTNP)
  Report
Delayed Quote. Delayed Nasdaq - 11/23 04:00:01 pm
0.184 USD   -10.02%
11/17TITAN PHARMACEUTICALS : Reports Third Quarter 2020 Financial Results
AQ
11/16TITAN PHARMACEUTICALS : 3Q Earnings Snapshot
AQ
11/16TITAN PHARMACEUTICALS : 3Q Earnings Snapshot
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Titan Pharmaceuticals : Enters into Definitive Agreement to Acquire JT Pharma's Kappa Opioid Agonist Peptide, JT-09

10/29/2020 | 08:50am EST

SOUTH SAN FRANCISCO - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that it has entered into a definitive asset purchase agreement (the 'Agreement') with JT Pharmaceuticals, Inc. ('JT Pharma'), a peptide drug development company, to acquire JT Pharma's kappa opioid agonist peptide, JT-09, for use in combination with Titan's ProNeura long-term, continuous drug delivery technology, for the treatment of chronic pruritus.

Under the terms of the Agreement, JT Pharma is entitled to receive from Titan future milestone payments based on the achievement of regulatory milestones, including potential regulatory approval for commercialization, plus single-digit percentage earn-out payments on net sales of the product.

'Current treatments for moderate to severe chronic pruritus, a debilitating condition characterized by itching of the skin lasting longer than six weeks, are relatively ineffective and are associated with undesirable side-effects,' said Dr. Kate DeVarney, President and Chief Operating Officer of Titan. 'Our early non-clinical data suggest that subcutaneous implantation of JT-09 ProNeura implants could potentially deliver therapeutic concentrations of JT-09 for six months or longer, and we are looking forward to conducting additional preclinical studies to establish proof-of-concept with data available in the first half of 2021.'

The closing of the agreement is subject to customary closing conditions and Titan's completion of a financing with gross proceeds of at least $8,000,000.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a commercial stage company developing proprietary therapeutics with its ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.

Forward-Looking Statements

This press release may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital, the winding down of U.S. commercial activities related to Probuphine, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Stephen Kilmer

Tel: (650) 989-2215

Email: skilmer@titanpharm.com

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about TITAN PHARMACEUTICALS, INC.
11/17TITAN PHARMACEUTICALS : Reports Third Quarter 2020 Financial Results
AQ
11/16TITAN PHARMACEUTICALS : 3Q Earnings Snapshot
AQ
11/16TITAN PHARMACEUTICALS : 3Q Earnings Snapshot
AQ
11/16TITAN PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
AQ
11/02TITAN PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Other Ev..
AQ
10/29TITAN PHARMACEUTICALS : Enters into Definitive Agreement to Acquire JT Pharma's ..
AQ
10/29TITAN PHARMACEUTICALS : Announces Pricing of $8.0 Million Underwritten Public Of..
AQ
10/28TITAN PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Financia..
AQ
10/27TITAN PHARMACEUTICALS : Announces Debt Settlement Agreement with Molteni and Hor..
AQ
10/26TITAN PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Financia..
AQ
More news
Financials (USD)
Sales 2020 5,23 M - -
Net income 2020 -15,9 M - -
Net Debt 2020 - - -
P/E ratio 2020 -1,15x
Yield 2020 -
Capitalization 36,2 M 36,2 M -
Capi. / Sales 2020 6,92x
Capi. / Sales 2021 7,12x
Nbr of Employees 21
Free-Float 94,9%
Chart TITAN PHARMACEUTICALS, INC.
Duration : Period :
Titan Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TITAN PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 0,80 $
Last Close Price 0,18 $
Spread / Highest target 335%
Spread / Average Target 335%
Spread / Lowest Target 335%
EPS Revisions
Managers
NameTitle
Kate DeVarney President, Chief Operating Officer & Director
Marc Rubin Executive Chairman
Brian E. Crowley Vice President-Finance
Sunil Bhonsle Director
M. David MacFarlane Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
TITAN PHARMACEUTICALS, INC.-5.20%36
JOHNSON & JOHNSON-1.37%378 744
ROCHE HOLDING AG-3.77%283 004
MERCK & CO., INC.-11.73%203 111
PFIZER INC.-6.79%202 993
NOVARTIS AG-13.38%198 168